speb/financial-data huggingface dataset:
Financial scorecard for NANO.L (Technology — Semiconductor Equipment & Materials, United Kingdom)
Report date: 2026-01-31 (quarterly)
Stock price: 0.00039999999999999996
Market cap: 4652254 (USD: 6461463.888888889)
P/E ratio: 0.08333333333333333
Debt to equity: -0.044328097731239094
Current ratio: 1.83
Buffett classification: The Gruesome
Analyst consensus upside (%): 875900
Rule of 40 score: 0
Piotroski F-score: 2 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 10.405278817536615
Total shareholder yield (%): 10.405278817536615 (High Return)
Momentum (%): 1m 1.3333333333333408, 3m -40.80000000000001, 6m -67.11111111111111, 12m -78.85714285714286, composite -62.348816485658595 (Strong Downtrend)
Lynch category:  (confidence: Low)
Screener: long score 1, short score 5, recommendation: Neutral
Revenue deceleration: no
Beneish M-score: -2.48256331682179 (Likely Safe)
ROE archetype: Standard Business
Treasury beta 1y: 0.007033329958216951 (R-squared: 0.00040211968979168416)
Insider 90-day net shares: -258105 (net value USD: 0.00)
Capital allocation category: Capital-Light Grower
Industry percentiles: P/E 5.769230769230769, P/B , ROIC , revenue growth 1y , 6m momentum 80.76923076923077
Sector percentiles: P/E 7.974641307974642, 6m momentum 82.9496162829496
Industry median P/E: 25.879310344827587; industry median ROIC: 12.426552026799476
Sector median P/E: 1.5433673469387754; sector median ROIC: 6.677876317240262
WACC: 0.054102338878605265
Base cash flow: -1481333.3333333335
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for NKL.V (Basic Materials — Other Industrial Metals & Mining, Canada)
Report date: 2026-04-30 (quarterly)
Stock price: 0.8156028368794326
Market cap: 98965808 (USD: 72237816.05839415)
P/E ratio: 30.900243309002434
P/B ratio: 1.330708783757631
Debt to equity: 0.39380000000000004
Current ratio: 1.04
Interest coverage ratio: -1.041130354250962
Return on net tangible assets (%): 2.5123238532663805
Buffett classification: The Gruesome
Rule of 40 score: 0
Altman Z-score: 1.4810097453298185 (Distress Zone)
Piotroski F-score: 4 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0.6118022095065399
Debt paydown yield (%): 0.07785428875185306
Total shareholder yield (%): 0.6896564982583929 (Low Return)
Momentum (%): 1m 3.4067882472137656, 3m -9.889041409288486, 6m 2.3210831721469836, 12m 47.89598108747046, composite 11.818505313754095 (Strong Uptrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 2, short score 9, recommendation: Short
Revenue deceleration: no
Accrual ratio: 0.019059520721585697
FCF conversion rate: -0.16704217939217827
Beneish M-score: -2.481162006648083 (Likely Safe)
ROE (%): 2.5170826039151537
Asset turnover: 0
Equity multiplier (leverage): 1.5412462940143046
ROE archetype: Low Return
Treasury beta 1y: 0.002806757960109191 (R-squared: 0.000613873309340884)
Insider 90-day net shares: 20000 (net value USD: 15100.00)
ROIC (%): -0.8455440594400484 (pretax: -1.0703089360000613)
Capital allocation category: Capital-Light Grower
Industry percentiles: P/E 13.98834304746045, P/B 20.06661115736886, ROIC 8.243130724396336, revenue growth 1y , 6m momentum 13.905079100749376
Sector percentiles: P/E 32.78734036646308, 6m momentum 19.933370349805664
Industry median P/E: 6.295008083084309; industry median ROIC: -14.271466134226909
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.06031601523491764
Base cash flow: -787748.1481481481
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for NMC.V (Basic Materials — Other Industrial Metals & Mining, Canada)
Report date: 2026-03-31 (quarterly)
Stock price: 0.3617021276595745
Market cap: 44545020 (USD: 32046776.97841727)
P/B ratio: 2.901130992685988
Debt to equity: 0
Current ratio: 1.56
Interest coverage ratio: -56.96343085106383
Return on net tangible assets (%): -5.5252973916808825
Buffett classification: The Gruesome
Rule of 40 score: 0
Altman Z-score: 0.06398035313665351 (Distress Zone)
Piotroski F-score: 3 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m -34.98518718017775, 3m -37.2744411527067, 6m -44.53900709219859, 12m -33.5250143760782, composite -26.522513455064857 (Flat)
Lynch category: Cyclical (confidence: High)
Screener: long score 2, short score 11, recommendation: Strong Short (Melting Ice Cube)
Revenue deceleration: no
Accrual ratio: 0.010948190001535312
FCF conversion rate: 1.2658157433513677
Beneish M-score: -2.3784156260934526 (Likely Safe)
ROE (%): -10.601044679593404
Asset turnover: 0
Equity multiplier (leverage): 2.57387255008546
ROE archetype: Low Return
Treasury beta 1y: 0.011511285487515763 (R-squared: 0.004129960958280588)
Insider 90-day net shares: 247500 (net value USD: 145047.00)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 34.970857618651124, ROIC , revenue growth 1y , 6m momentum 57.951706910907575
Sector percentiles: P/E , 6m momentum 67.129372570794
Industry median P/E: 6.295008083084309; industry median ROIC: -14.271466134226909
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.10300000000000001
Base cash flow: -7903217.518248174
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for NMI.V (Basic Materials — Other Industrial Metals & Mining, Canada)
Report date: 2026-02-28 (quarterly)
Stock price: 0.14893617021276595
Market cap: 47885292 (USD: 34952767.88321168)
P/B ratio: 2.694131866256049
Debt to equity: 0
Current ratio: 1.99
Return on net tangible assets (%): -0.6365988849044855
Buffett classification: The Gruesome
Rule of 40 score: 0
Altman Z-score: 35.89066390328348 (Safe Zone)
Piotroski F-score: 3 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m 11.310190369540855, 3m -27.127659574468087, 6m -41.276595744680854, 12m 102.55319148936168, composite 4.52252522225552 (Strong Uptrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 6, short score 7, recommendation: Neutral
Revenue deceleration: no
Accrual ratio: -0.008324897778848773
FCF conversion rate: -0.30408780475712394
Beneish M-score: -2.726620499497084 (Likely Safe)
ROE (%): -0.6540608572634223
Asset turnover: 0
Equity multiplier (leverage): 1.024580493580753
ROE archetype: Low Return
Treasury beta 1y: -0.008871281376040766 (R-squared: 0.0006021190572199199)
Insider 90-day net shares: 0 (net value USD: 0.00)
ROIC (%): -2.7021178514522974 (pretax: -3.4204023436105033)
Capital allocation category: Capital-Light Grower
Industry percentiles: P/E , P/B 33.72189841798502, ROIC 10.574521232306411, revenue growth 1y , 6m momentum 54.45462114904246
Sector percentiles: P/E , 6m momentum 64.54747362576346
Industry median P/E: 6.295008083084309; industry median ROIC: -14.271466134226909
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.1019
Base cash flow: -663496.4285714286
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for NMIH (Financial Services — Insurance - Specialty, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 42.75
Market cap: 3247798272 (USD: 3247798272)
P/E ratio: 7.427722772277227
P/B ratio: 1.0825372246690512
Debt to equity: 0.1617
Current ratio: 1.81
Return on net tangible assets (%): 3.831066517853407
Buffett classification: The Gruesome
Analyst consensus upside (%): 25.299920021327654
Rule of 40 score: 61.63755755576171
Piotroski F-score: 6 (Neutral)
Dividend yield (%): 0
Buyback yield (%): 0.8521157314046383
Debt paydown yield (%): -0.015117934024197916
Total shareholder yield (%): 0.8369977973804403 (Low Return)
Momentum (%): 1m 8.365019011406837, 3m 3.9892970080272456, 6m 13.275039745627975, 12m 12.322648449816073, composite 6.972154990752476 (Flat)
Lynch category: Slow Grower (confidence: Medium)
Screener: long score 5, short score 2, recommendation: Neutral
Revenue growth 1y (%): 5.90432102328482
Net income growth 1y (%): -3.148431634473814
Revenue deceleration: no
Accrual ratio: -0.004041164606819275
FCF conversion rate: 1.157666364643109
Beneish M-score: -2.4644693687489965 (Likely Safe)
ROE (%): 3.8025288175639855
Net margin (%): 54.138165962665205
Asset turnover: 0.047343890954355816
Equity multiplier (leverage): 1.483559699855563
ROE archetype: Low Return
P/E z-score: 4.914752348827112
FCF z-score: 4.914752348827115
Treasury beta 1y: -0.009460082547006326 (R-squared: 0.03023026295655952)
Insider 90-day net shares: -97466 (net value USD: -3700133.00)
Capital allocation category: Standard Allocator
Industry percentiles: P/E 21.73913043478261, P/B 43.47826086956522, ROIC , revenue growth 1y 43.47826086956522, 6m momentum 39.130434782608695
Sector percentiles: P/E 26.487325400931194, 6m momentum 18.804966373512674
Industry median P/E: 9.39977249365699; industry median ROIC: 
Sector median P/E: 9.286368843069873; sector median ROIC: 1.3915857507207385
WACC: 0.07381717042889416
Base cash flow: 393405000
DCF price per share: base 204.9997791539707, conservative 126.87247030303762, aggressive 335.8596418885848
Financial scorecard for NRXS (Healthcare — Biotechnology, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 6.8
Market cap: 84213960 (USD: 84213960)
P/B ratio: 15.944984732625207
Debt to equity: 0.061500000000000006
Current ratio: 2.89
Interest coverage ratio: -66.46603535835656
Return on net tangible assets (%): -31.839028829481038
Buffett classification: The Gruesome
Analyst consensus upside (%): 48.64864864864864
Rule of 40 score: -33.999585354809085
Altman Z-score: 6.4882982041103485 (Safe Zone)
Piotroski F-score: 7 (Neutral)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.07491513283545863
Total shareholder yield (%): 0.07491513283545863 (Low Return)
Momentum (%): 1m 0, 3m -13.486005089058532, 6m 39.917695473251015, 12m 146.3768115942029, composite 57.60283399279846 (Strong Uptrend)
Lynch category: Speculative (confidence: Low)
Screener: long score 6, short score 7, recommendation: Neutral
Revenue growth 1y (%): 79.5203510280186
Revenue deceleration: no
Accrual ratio: -0.07018931411505226
FCF conversion rate: 0.6981575218345074
Beneish M-score: -1.9789704398575514 (Likely Safe)
ROE (%): -38.51420182658166
Net margin (%): -109.54976201626611
Asset turnover: 0.2122653969948795
Equity multiplier (leverage): 1.6562666654422111
ROE archetype: Low Return
Treasury beta 1y: 0.017456134558868484 (R-squared: 0.011107176075703221)
Insider 90-day net shares: 96320 (net value USD: 499978.00)
Incremental ROIC 3y (%): -86.32538053371549 (pretax: -109.27263358698163)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B 61.191335740072205, ROIC , revenue growth 1y 6.588447653429603, 6m momentum 10.288808664259928
Sector percentiles: P/E , 6m momentum 8.094555873925502
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.1251122692765941
Base cash flow: -7772204
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for NVI.V (Technology — Communication Equipment, Canada)
Report date: 2026-03-31 (quarterly)
Stock price: 0.0921985815602837
Market cap: 4604638 (USD: 3312689.2086330936)
P/E ratio: 9.352517985611511
P/B ratio: 3.6445937759217863
Debt to equity: 2.4457
Current ratio: 1.46
Interest coverage ratio: -21.16930769230769
Return on net tangible assets (%): -299.8198882439104
Buffett classification: The Gruesome
Rule of 40 score: -50.82261013753903
Altman Z-score: -1.3843938283502137 (Distress Zone)
Piotroski F-score: 5 (Neutral)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 32.6554592593682
Total shareholder yield (%): 32.6554592593682 (High Return)
Momentum (%): 1m -18.17375886524822, 3m -9.777102330293811, 6m 112.05673758865251, 12m 39.322301024428725, composite 57.51522531564488 (Strong Uptrend)
Lynch category: Slow Grower (confidence: Low)
Screener: long score 0, short score 16, recommendation: Strong Short (Melting Ice Cube)
Revenue growth 1y (%): -34.00159182998428
Net income growth 1y (%): -87.57539234531848
Revenue deceleration: no
Revenue growth consistency score: 51.303319729773904
Accrual ratio: 0.02444175469277174
FCF conversion rate: -1.368519138651486
Beneish M-score: -3.750424374243589 (Likely Safe)
Net margin (%): 7.691265397536394
Asset turnover: 0.13417069985704902
ROE archetype: Standard Business
P/E z-score: 2.6758589394181302
FCF z-score: 2.6719763847127287
Treasury beta 1y: -0.00011485742277425571 (R-squared: 1.1593649369733361e-07)
Insider 90-day net shares: 50000 (net value USD: 8150.00)
ROIC (%): 243.98080335345927 (pretax: 243.98080335345927)
Capital allocation category: Capital-Light Grower
Industry percentiles: P/E 28.08988764044944, P/B 54.49438202247191, ROIC 0, revenue growth 1y 62.92134831460674, 6m momentum 10.674157303370785
Sector percentiles: P/E 33.7671004337671, 6m momentum 3.1698365031698366
Industry median P/E: 9.556693775414452; industry median ROIC: 4.443932929219476
Sector median P/E: 1.5433673469387754; sector median ROIC: 6.677876317240262
WACC: 0.05996875544045279
Base cash flow: 821095.6204379562
DCF price per share: base 0.5883733130387191, conservative 0.4814004920740836, aggressive 0.7336594498628222
Financial scorecard for OBD.L (Healthcare — Diagnostics & Research, United Kingdom)
Report date: 2026-03-31 (quarterly)
Stock price: 0
Market cap: 5363638 (USD: 7057418.421052632)
P/B ratio: 0
Debt to equity: 1.3161
Current ratio: 2.01
Buffett classification: The Gruesome
Rule of 40 score: 0
Piotroski F-score: 3 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 18.068615651077405
Total shareholder yield (%): 18.068615651077405 (High Return)
Momentum (%): 1m , 3m , 6m , 12m -100, composite  ()
Lynch category: Asset Play (confidence: High)
Screener: long score 0, short score 2, recommendation: Neutral
Revenue deceleration: no
Beneish M-score: -2.4490608391118145 (Likely Safe)
Equity multiplier (leverage): 3.9549566157854623
ROE archetype: Standard Business
Treasury beta 1y: 10.689210301752873 (R-squared: 0.007839208899782431)
Insider 90-day net shares: 0 (net value USD: 0.00)
ROIC (%): -175.59731127197517 (pretax: -222.27507755946223)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 72.79411764705883, ROIC 73.52941176470588, revenue growth 1y , 6m momentum 
Industry median P/E: 21.640734060420083; industry median ROIC: 2.9089897435686405
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.05
Base cash flow: -13474324.324324323
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for OBI.L (Healthcare — Biotechnology, Canada)
Report date: 2025-12-31 (annual)
Stock price: 0.0018666666666666669
Market cap: 71438328 (USD: 52144764.963503644)
P/B ratio: 0.24840317966729997
Debt to equity: 0.1185
Current ratio: 1.23
Interest coverage ratio: -1427
Return on net tangible assets (%): -833.4002869440459
Buffett classification: The Gruesome
Rule of 40 score: -911.7312912608924
Altman Z-score: -33.213247368698354 (Distress Zone)
Piotroski F-score: 3 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.19877284921897947
Total shareholder yield (%): 0.19877284921897947 (Low Return)
Momentum (%): 1m -5.422222222222215, 3m 6.256410256410278, 6m 53.48148148148151, 12m -1.3333333333333328, composite 21.353733336189492 (Flat)
Lynch category: Asset Play (confidence: High)
Screener: long score 2, short score 11, recommendation: Strong Short (Melting Ice Cube)
Revenue growth 1y (%): 34.79176240501862
Revenue CAGR 3y (%): 60.27378776902135
Revenue deceleration: yes
Revenue growth consistency score: 73.6553853829416
Beneish M-score: -2.4648886491839272 (Likely Safe)
Equity multiplier (leverage): 5.495131797672762
ROE archetype: Standard Business
Treasury beta 1y: -0.00040166977788238416 (R-squared: 1.0536037523978605e-05)
Insider 90-day net shares: 0 (net value USD: 0.00)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 2.3465703971119134, ROIC , revenue growth 1y 10.740072202166065, 6m momentum 7.851985559566788
Sector percentiles: P/E , 6m momentum 5.802292263610315
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.06439776006101701
Base cash flow: -21199999.999999996
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for OR3.AX (Basic Materials — Other Industrial Metals & Mining, Australia)
Report date: 2025-06-30 (annual)
Stock price: 0.04861111111111112
Market cap: 60403924 (USD: 39479688.88888889)
Debt to equity: 0.002
Current ratio: 17.69
Buffett classification: The Gruesome
Rule of 40 score: 0
Piotroski F-score: 1 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m -11.892361111111107, 3m -2.7777777777777812, 6m -11.284722222222214, 12m 144.67592592592595, composite 54.5462164750958 (Strong Uptrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 2, short score 2, recommendation: Neutral
Revenue deceleration: no
Beneish M-score: -2.48 (Likely Safe)
ROE archetype: Standard Business
Treasury beta 1y: 0.001202958051200405 (R-squared: 6.317840085524204e-06)
Insider 90-day net shares: 7560236 (net value USD: 358664.00)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B , ROIC , revenue growth 1y , 6m momentum 27.477102414654453
Sector percentiles: P/E , 6m momentum 36.00777345918934
Industry median P/E: 6.295008083084309; industry median ROIC: -14.271466134226909
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.12665
Base cash flow: 0
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for ORCA.L (Energy — Oil & Gas E&P, United Kingdom)
Report date: 2025-12-31 (quarterly)
Stock price: 0.0026666666666666666
Market cap: 15841069 (USD: 21406850)
P/B ratio: 0.1118817995716703
Debt to equity: 1.7281
Current ratio: 0.12
Buffett classification: The Gruesome
Rule of 40 score: 0
Piotroski F-score: 2 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): -2.516835040251803
Total shareholder yield (%): -2.516835040251803 (Minimal or Negative)
Momentum (%): 1m 68.88888888888891, 3m 9.629629629629632, 6m 3.8596491228070047, 12m 97.33333333333331, composite 10.110461338531502 (Moderate Uptrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 0, short score 2, recommendation: Neutral
Revenue deceleration: no
Beneish M-score: -3.746037605857068 (Likely Safe)
Equity multiplier (leverage): 4.264583891296355
ROE archetype: Standard Business
Treasury beta 1y: 0.012155212602900527 (R-squared: 0.003747695448001651)
Insider 90-day net shares: 0 (net value USD: 0.00)
ROIC (%): -28.84657258200582 (pretax: -36.51464883798205)
Capital allocation category: Capital-Light Grower
Industry percentiles: P/E , P/B 10.36036036036036, ROIC 64.63963963963964, revenue growth 1y , 6m momentum 43.01801801801802
Sector percentiles: P/E , 6m momentum 43.70664023785927
Industry median P/E: 11.260253542132737; industry median ROIC: 0.8337488598897688
Sector median P/E: 11.598358576086895; sector median ROIC: 4.629877910100043
WACC: 0.08175563538083364
Base cash flow: -1377376.712328767
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for ORCL.V (Financial Services — Asset Management, Canada)
Report date: 2025-12-31 (quarterly)
Stock price: 0.02127659574468085
Market cap: 3434746 (USD: 2507113.8686131383)
P/B ratio: 47.856753525777705
Debt to equity: 0
Current ratio: 0.895378623714526
Return on net tangible assets (%): -174.60854880913564
Buffett classification: The Gruesome
Rule of 40 score: 0
Altman Z-score: -23.647771990764074 (Distress Zone)
Piotroski F-score: 4 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m 0.7092198581560277, 3m -27.127659574468083, 6m -51.06382978723404, 12m -3.546099290780135, composite -27.47228049145939 (Moderate Downtrend)
Lynch category: Turnaround (confidence: High)
Screener: long score 2, short score 10, recommendation: Strong Short (Melting Ice Cube)
Revenue deceleration: no
Accrual ratio: -0.15681341358061102
FCF conversion rate: 0.4147128527996553
Beneish M-score: -3.1223418032665666 (Likely Safe)
ROE (%): -176.7982277935867
Asset turnover: 0
Equity multiplier (leverage): 6.59878055152416
ROE archetype: Low Return
Treasury beta 1y: 0.0020157558059152015 (R-squared: 7.669874524839601e-06)
Insider 90-day net shares: -6500110 (net value USD: -112904.00)
ROIC (%): -134.6613100229259 (pretax: -170.45735445939988)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 79.48951686417503, ROIC 22.333637192342753, revenue growth 1y , 6m momentum 84.41203281677302
Sector percentiles: P/E , 6m momentum 68.15830315571651
Industry median P/E: 7.917582417582417; industry median ROIC: 1.6915626385800535
Sector median P/E: 9.286368843069873; sector median ROIC: 1.3915857507207385
WACC: 0.1019
Base cash flow: -4701200
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for ORCP.L (Energy — Thermal Coal, United Kingdom)
Report date: 2025-12-31 (annual)
Stock price: 0
Market cap: 7212843 (USD: 9747085.135135135)
P/B ratio: 0
Debt to equity: 0
Current ratio: 4.01
Return on net tangible assets (%): -28.177906156531883
Buffett classification: The Gruesome
Rule of 40 score: 0
Altman Z-score: 20.51136005120682 (Safe Zone)
Piotroski F-score: 1 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Lynch category: Cyclical (confidence: High)
Screener: long score 4, short score 9, recommendation: Short
Revenue deceleration: no
Accrual ratio: 0.025626401803064823
FCF conversion rate: 1.3029919348757437
Beneish M-score: -2.49566158657257 (Likely Safe)
ROE (%): -8.688550116245485
Asset turnover: 0
Equity multiplier (leverage): 1.0272845291418335
ROE archetype: Low Return
Treasury beta 1y: 24.999999999999993 (R-squared: 0.0508160912136093)
Insider 90-day net shares: 0 (net value USD: 0.00)
ROIC (%): -7.8593957377021475 (pretax: -9.94860219962297)
Incremental ROIC 3y (%): 63.15918473597375 (pretax: 79.94833510882754)
Capital allocation category: Turnaround Compounder
Industry percentiles: P/E , P/B 74.50980392156863, ROIC 60.78431372549019, revenue growth 1y , 6m momentum 
Industry median P/E: 1.6213917999632284; industry median ROIC: 5.423977083364904
Sector median P/E: 11.598358576086895; sector median ROIC: 4.629877910100043
WACC: 0.15
Base cash flow: -966285.1351351351
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for ORE.TO (Basic Materials — Gold, Canada)
Report date: 2026-03-31 (quarterly)
Stock price: 1.602836879432624
Market cap: 1507347328 (USD: 1084422538.1294966)
P/E ratio: 8.489208633093526
P/B ratio: 2.7944060091179583
Debt to equity: 0.1979
Current ratio: 0.79
Interest coverage ratio: 19.753072371415566
Return on net tangible assets (%): 1.54441362529518
Buffett classification: The Good
Analyst consensus upside (%): 149.1398305084746
Rule of 40 score: 107.10394264650981
Altman Z-score: 1.4974864602184474 (Distress Zone)
Piotroski F-score: 6 (Neutral)
Magic formula: return on capital % 10.5590409697359, earnings yield % 3.92604140564285, rank 166
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.6923987471717284
Total shareholder yield (%): 0.6923987471717284 (Low Return)
Momentum (%): 1m 4.404971045611275, 3m -2.405043341213555, 6m -7.83687943262413, 12m 92.90780141843975, composite 24.842288985229995 (Strong Uptrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 6, short score 4, recommendation: Neutral
Revenue growth 1y (%): 131.2624479392488
Net income growth 1y (%): 172.83324403959398
Revenue deceleration: no
Accrual ratio: -0.07672210072875878
FCF conversion rate: 2.5570848375451267
Beneish M-score: -3.2081540681886547 (Likely Safe)
ROE (%): 9.951407981349172
Net margin (%): 26.219492519011713
Asset turnover: 0.18792472718451803
Equity multiplier (leverage): 2.019650965341214
ROE archetype: Standard Business
P/E z-score: 4.471064281123979
Treasury beta 1y: -0.004355366042809785 (R-squared: 0.0008323197003436972)
Insider 90-day net shares: -103000 (net value USD: -112594.00)
ROIC (%): 22.742432491919885 (pretax: 34.98835767987675)
Incremental ROIC 3y (%): 39.338628257166555 (pretax: 60.80515054577773)
Capital allocation category: High-Efficiency Compounder
Industry percentiles: P/E 13.314447592067987, P/B 30.31161473087819, ROIC 7.507082152974505, revenue growth 1y 3.6827195467422094, 6m momentum 17.280453257790366
Sector percentiles: P/E 24.486396446418656, 6m momentum 33.09272626318712
Industry median P/E: 8.322060300477567; industry median ROIC: -7.9824265928961236
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.11351756925232899
Base cash flow: -20864963.503649622
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for ORIC (Healthcare — Biotechnology, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 12.1
Market cap: 1252562560 (USD: 1252562560)
P/B ratio: 3.1561675306636636
Debt to equity: 0.016200000000000003
Current ratio: 16.33
Return on net tangible assets (%): -8.542510413733856
Buffett classification: The Gruesome
Analyst consensus upside (%): 63.29913180741911
Rule of 40 score: 0
Altman Z-score: 33.557201424527946 (Safe Zone)
Piotroski F-score: 4 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.0027144352773884606
Total shareholder yield (%): 0.0027144352773884606 (Low Return)
Momentum (%): 1m 28.31389183457052, 3m 18.164062499999993, 6m 0.9174311926605456, 12m 3.154305200340999, composite -0.17544981486478997 (Strong Downtrend)
Lynch category: Speculative (confidence: Low)
Screener: long score 4, short score 8, recommendation: Short
Revenue deceleration: no
Accrual ratio: -0.007868484908685842
FCF conversion rate: 0.906981295607683
Beneish M-score: -2.430394655597739 (Likely Safe)
ROE (%): -8.942655443863691
Asset turnover: 0
Equity multiplier (leverage): 1.0571720386689152
ROE archetype: Low Return
Treasury beta 1y: -0.004016120311479808 (R-squared: 0.0004584914545637105)
Insider 90-day net shares: -300 (net value USD: -3600.00)
ROIC (%): -106.37373356935709 (pretax: -134.65029565741403)
Incremental ROIC 3y (%): -50.793714128918666 (pretax: -64.2958406695173)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B 34.74729241877256, ROIC 25.451263537906136, revenue growth 1y , 6m momentum 27.527075812274372
Sector percentiles: P/E , 6m momentum 27.97277936962751
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.10225571231683468
Base cash flow: -128960000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for PEPG (Healthcare — Biotechnology, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 1.93
Market cap: 133496584 (USD: 133496584)
P/B ratio: 0.9137894502910883
Debt to equity: 0.12359999999999999
Current ratio: 14.98
Return on net tangible assets (%): -12.320495596357665
Buffett classification: The Gruesome
Analyst consensus upside (%): 479.0960451977401
Rule of 40 score: 0
Altman Z-score: 0.7577664082269382 (Distress Zone)
Piotroski F-score: 2 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.33184369721400514
Total shareholder yield (%): 0.33184369721400514 (Low Return)
Momentum (%): 1m 9.039548022598867, 3m 25.324675324675315, 6m -64.58715596330276, 12m 34.02777777777778, composite -5.44860465732026 (Moderate Uptrend)
Lynch category: Turnaround (confidence: High)
Screener: long score 2, short score 11, recommendation: Strong Short (Melting Ice Cube)
Revenue deceleration: no
Accrual ratio: 0.004015723708517816
FCF conversion rate: 1.0373247762202331
Beneish M-score: -2.4291889781653184 (Likely Safe)
ROE (%): -12.623656830973903
Asset turnover: 0
Equity multiplier (leverage): 1.1733256580817557
ROE archetype: Low Return
Treasury beta 1y: 0.012605045899969296 (R-squared: 0.0010632212697837152)
Insider 90-day net shares: -10471 (net value USD: -59312.00)
ROIC (%): -462.4404702351176 (pretax: -585.367683841921)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 10.198555956678701, ROIC 37.274368231046935, revenue growth 1y , 6m momentum 71.75090252707581
Sector percentiles: P/E , 6m momentum 74.67765042979943
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.1467540157606857
Base cash flow: -84774000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for PHR (Healthcare — Health Information Services, United States)
Report date: 2026-04-30 (quarterly)
Stock price: 10.22
Market cap: 631717504 (USD: 631717504)
P/E ratio: 57.56250000000001
P/B ratio: 1.585361602077474
Debt to equity: 0.25780000000000003
Current ratio: 1.76
Interest coverage ratio: 2.935624184428012
Return on net tangible assets (%): 14.890488218400746
Buffett classification: The Good
Analyst consensus upside (%): 51.357220412594984
Rule of 40 score: 5.196276298224175
Altman Z-score: -0.0015456336556924632 (Distress Zone)
Piotroski F-score: 8 (Strong)
Magic formula: return on capital % 4.908756336870586, earnings yield % 1.0389974075590658, rank 1326
Dividend yield (%): 0
Buyback yield (%): 0.17333697310372456
Debt paydown yield (%): 1.5658898063397657
Total shareholder yield (%): 1.7392267794434904 (Low Return)
Momentum (%): 1m 6.569343065693439, 3m 7.127882599580729, 6m -35.47979797979798, 12m -62.21811460258779, composite -30.966350105174083 (Strong Downtrend)
Lynch category: Slow Grower (confidence: Low)
Screener: long score 7, short score 6, recommendation: Neutral
Revenue growth 1y (%): 12.937310240132494
Revenue deceleration: no
Revenue growth consistency score: 2.060589370311926
Accrual ratio: -0.020164955926284898
FCF conversion rate: 5.525480931488357
Beneish M-score: -2.5876308695705106 (Likely Safe)
ROE (%): 0.8510736079575238
Net margin (%): 2.262954901286898
Asset turnover: 0.19690495221180648
Equity multiplier (leverage): 1.9100053569094797
ROE archetype: Low Return
P/E z-score: 1.4015658790406975
FCF z-score: 2.8622569161791276
Treasury beta 1y: 0.011617988746466504 (R-squared: 0.007642579320878508)
Insider 90-day net shares: -13634 (net value USD: -130561.00)
ROIC (%): -1.427859146151449 (pretax: -1.8074166406980368)
Incremental ROIC 3y (%): 54.68314936255142 (pretax: 69.21917640829294)
Capital allocation category: Turnaround Compounder
Industry percentiles: P/E 33.1578947368421, P/B 21.578947368421055, ROIC 34.73684210526316, revenue growth 1y 22.105263157894736, 6m momentum 63.68421052631579
Sector percentiles: P/E 31.769340974212035, 6m momentum 62.213467048710605
Industry median P/E: 8.33027298322928; industry median ROIC: 0.6291287571896624
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.09023118050135037
Base cash flow: 22658000
DCF price per share: base 14.333475411454119, conservative 7.863414482698699, aggressive 26.002596069470908
Financial scorecard for PLY.AX (Communication Services — Electronic Gaming & Multimedia, Australia)
Report date: 2025-06-30 (annual)
Stock price: 0.06944444444444445
Market cap: 47652636 (USD: 31145513.725490194)
P/B ratio: 1.84809594869054
Debt to equity: 0.0126
Current ratio: 1.93
Interest coverage ratio: -2742.8333333333335
Return on net tangible assets (%): -55.03223033949291
Buffett classification: The Gruesome
Analyst consensus upside (%): 225.12500000000003
Rule of 40 score: -72.40330762082436
Altman Z-score: 1.6632088577018873 (Distress Zone)
Piotroski F-score: 2 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 1.9156967518019363
Total shareholder yield (%): 1.9156967518019363 (Low Return)
Momentum (%): 1m -16.08796296296296, 3m -67.5925925925926, 6m -65.03831417624521, 12m -54.408212560386474, composite -59.43269106187646 (Strong Downtrend)
Lynch category:  (confidence: Low)
Screener: long score 2, short score 2, recommendation: Neutral
Revenue deceleration: no
Accrual ratio: 0.1655195366723269
FCF conversion rate: 1.8609895102007104
Beneish M-score: -2.294351650659854 (Likely Safe)
Equity multiplier (leverage): 1.4106538393016212
ROE archetype: Standard Business
Treasury beta 1y: 0.00204762960572859 (R-squared: 6.970835822021336e-05)
Insider 90-day net shares: 703166 (net value USD: 45729.00)
ROIC (%): -48.17694360038539 (pretax: -60.983472911880234)
Incremental ROIC 3y (%): -105.95706510626069 (pretax: -125.93212361664116)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B 43.2, ROIC 74.4, revenue growth 1y , 6m momentum 89.60000000000001
Sector percentiles: P/E , 6m momentum 81.36696501220506
Industry median P/E: 0.634833652550188; industry median ROIC: 5.123301786907901
Sector median P/E: 1.436628982900151; sector median ROIC: 4.830798676039866
WACC: 0.12308640685877742
Base cash flow: -4184967.320261438
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for PROK (Healthcare — Biotechnology, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 1.5
Market cap: 453089408 (USD: 453089408)
P/B ratio: 1.3960543597588786
Debt to equity: 0.0144
Current ratio: 9.06
Interest coverage ratio: -2995.5333333333333
Buffett classification: The Gruesome
Analyst consensus upside (%): 249.16201117318434
Rule of 40 score: -20615.753311539025
Altman Z-score: 3.3425441234825106 (Safe Zone)
Piotroski F-score: 2 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.055838868782383894
Total shareholder yield (%): 0.055838868782383894 (Low Return)
Momentum (%): 1m -15.254237288135593, 3m -22.680412371134018, 6m -30.87557603686636, 12m -53.987730061349694, composite -33.087169960131 (Strong Downtrend)
Lynch category: Turnaround (confidence: Medium)
Screener: long score 4, short score 7, recommendation: Neutral
Revenue growth 1y (%): -1.7391304347826098
Revenue deceleration: no
Accrual ratio: 0.08094748535070771
FCF conversion rate: 2.2692518840145732
Beneish M-score: 11.870136823015208 (Strong Manipulation Signal)
ROE (%): -7.106616988563514
Net margin (%): -8865.929203539823
Asset turnover: 0.0007193351560734485
Equity multiplier (leverage): 1.1143134295802248
ROE archetype: Low Return
Treasury beta 1y: 0.002227884665533824 (R-squared: 0.00012817579947693153)
Insider 90-day net shares: 0 (net value USD: 0.00)
ROIC (%): -374.45573365506147 (pretax: -473.994599563369)
Incremental ROIC 3y (%): -53.48076272142615 (pretax: -67.69716800180525)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B 15.884476534296029, ROIC 35.83032490974729, revenue growth 1y 18.501805054151625, 6m momentum 52.43682310469314
Sector percentiles: P/E , 6m momentum 58.77507163323782
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.13809431773555048
Base cash flow: -77607000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for PRTC.L (Healthcare — Biotechnology, United States)
Report date: 2025-12-31 (annual)
Stock price: 0.0164
Market cap: 299404384 (USD: 299404384)
P/B ratio: 0.013451477217707638
Debt to equity: 0.6648999999999999
Current ratio: 6.59
Interest coverage ratio: -2.152281713524259
Return on net tangible assets (%): -34.24160117121282
Buffett classification: The Gruesome
Analyst consensus upside (%): 2161173.5999999996
Rule of 40 score: -1995.8698361511144
Piotroski F-score: 2 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.44488326530315603
Total shareholder yield (%): 0.44488326530315603 (Low Return)
Momentum (%): 1m -6.985074626865667, 3m -1.3333333333333264, 6m -10.103703703703701, 12m -15.132867132867128, composite -6.732232809425788 (Moderate Downtrend)
Lynch category: Turnaround (confidence: High)
Screener: long score 1, short score 2, recommendation: Neutral
Revenue growth 1y (%): 7.972190034762461
Net income growth 1y (%): -305.0812932162213
Revenue CAGR 3y (%): 30.631769017667978
Revenue deceleration: yes
Revenue growth consistency score: 292.8672340692144
Accrual ratio: -0.04326215879966061
FCF conversion rate: 0.775813521172965
Beneish M-score: -2.4440831072109974 (Likely Safe)
ROE (%): -30.75605828962359
Net margin (%): -2355.4196179437645
Asset turnover: 0.008192764728380571
Equity multiplier (leverage): 1.5937929594497828
ROE archetype: Low Return
Treasury beta 1y: 0.01947820783591587 (R-squared: 0.0517614021840735)
Insider 90-day net shares: 147849 (net value USD: 234931.00)
ROIC (%): -162.27743724460012 (pretax: -205.41447752481025)
Capital allocation category: Capital-Light Grower
Industry percentiles: P/E , P/B 0.18050541516245489, ROIC 29.51263537906137, revenue growth 1y 15.342960288808664, 6m momentum 35.28880866425993
Sector percentiles: P/E , 6m momentum 40.222063037249285
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.15
Base cash flow: -106653000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for PUMP (Energy — Oil & Gas Equipment & Services, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 11.8
Market cap: 1446880384 (USD: 1446880384)
P/B ratio: 1.7871537142816687
Debt to equity: 0.1893
Current ratio: 1.64
Interest coverage ratio: -3.29466966966967
Return on net tangible assets (%): -0.6833340459190217
Buffett classification: The Gruesome
Analyst consensus upside (%): 30.256766134628727
Rule of 40 score: -23.291681198794134
Altman Z-score: 2.301479368871824 (Grey Zone)
Piotroski F-score: 5 (Neutral)
Magic formula: return on capital % 1.8952745483520554, earnings yield % 1.2541998264402419, rank 5138
Dividend yield (%): 0
Buyback yield (%): 0.059922023243076876
Debt paydown yield (%): 1.804157433376331
Total shareholder yield (%): 1.8640794566194079 (Low Return)
Momentum (%): 1m -15.593705293276106, 3m -30.588235294117645, 6m 7.861060329067652, 12m 93.4426229508197, composite 35.4843843012675 (Strong Uptrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 3, short score 8, recommendation: Short
Revenue growth 1y (%): -24.687548690097273
Net income growth 1y (%): -137.94001249739637
Revenue deceleration: no
Accrual ratio: 0.02739547457689886
FCF conversion rate: 11.153170463903376
Beneish M-score: -1.9864027490305751 (Likely Safe)
ROE (%): -0.4006565796817734
Net margin (%): -1.3458448011526312
Asset turnover: 0.20048513128170944
Equity multiplier (leverage): 1.4848928933772887
ROE archetype: Low Return
P/E z-score: 3.071869661049734
FCF z-score: 3.071869661049734
Treasury beta 1y: -0.007209838468290935 (R-squared: 0.0015360075565409195)
Insider 90-day net shares: -16600000 (net value USD: -276556000.00)
ROIC (%): 1.2654652092551166 (pretax: 1.9468695527001794)
Incremental ROIC 3y (%): -141.34792644818867 (pretax: -217.45834838182873)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B 50.75757575757576, ROIC 66.66666666666666, revenue growth 1y 64.39393939393939, 6m momentum 37.878787878787875
Sector percentiles: P/E , 6m momentum 40.53518334985134
Industry median P/E: 14.518489818761033; industry median ROIC: 5.879956809181115
Sector median P/E: 11.598358576086895; sector median ROIC: 4.629877910100043
WACC: 0.07747527577497346
Base cash flow: -10596000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for PVIS.V (Financial Services — Asset Management, Canada)
Report date: 2025-12-31 (quarterly)
Stock price: 0.2907801418439716
Market cap: 10976412 (USD: 8011979.562043795)
P/B ratio: 62.561501970742704
Debt to equity: 3.9621
Current ratio: 1.6
Interest coverage ratio: -17.1041634541249
Return on net tangible assets (%): -363.94397794014554
Buffett classification: The Gruesome
Rule of 40 score: -25.57412788867891
Altman Z-score: -1.895861695946219 (Distress Zone)
Piotroski F-score: 3 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): -0.1498006253131679
Total shareholder yield (%): -0.1498006253131679 (Minimal or Negative)
Momentum (%): 1m 25.12357618740595, 3m 73.20382362010484, 6m 100.63829787234036, 12m 339.4011032308905, composite 141.6719434708777 (Strong Uptrend)
Lynch category: Turnaround (confidence: High)
Screener: long score 0, short score 13, recommendation: Strong Short (Melting Ice Cube)
Revenue growth 1y (%): 217.05491854590244
Revenue deceleration: no
Accrual ratio: -0.15429412699757217
FCF conversion rate: 0.3802699763290896
Beneish M-score: -4.3600121931349936 (Likely Safe)
ROE (%): -135.75552601492146
Net margin (%): -36.724442550952006
Asset turnover: 0.6779406050503283
Equity multiplier (leverage): 5.4526881215646
ROE archetype: Low Return
Treasury beta 1y: -0.01189622709799064 (R-squared: 0.0019534847589773225)
Insider 90-day net shares: 50000 (net value USD: 7300.00)
Incremental ROIC 3y (%): -3037.9938951209783 (pretax: -3845.5618925582003)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B 79.58067456700091, ROIC , revenue growth 1y 2.917046490428441, 6m momentum 0.27347310847766637
Sector percentiles: P/E , 6m momentum 0.5173305742369374
Industry median P/E: 7.917582417582417; industry median ROIC: 1.6915626385800535
Sector median P/E: 9.286368843069873; sector median ROIC: 1.3915857507207385
WACC: 0.07165
Base cash flow: -1105300
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for PVL.AX (Financial Services — Asset Management, Australia)
Report date: 2025-06-30 (annual)
Stock price: 0.09027777777777779
Market cap: 21718502 (USD: 14195099.346405229)
Current ratio: 2.51
Buffett classification: The Gruesome
Rule of 40 score: 0
Piotroski F-score: 1 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m -6.498015873015872, 3m 5.324074074074088, 6m -5.853174603174599, 12m 51.46604938271607, composite 20.48774554521682 (Strong Uptrend)
Lynch category:  (confidence: Low)
Screener: long score 0, short score 2, recommendation: Neutral
Revenue deceleration: no
Revenue growth consistency score: 132.9343399951401
Beneish M-score: -2.48 (Likely Safe)
ROE archetype: Standard Business
Treasury beta 1y: -0.0006366950977447013 (R-squared: 1.3815569295091504e-05)
Insider 90-day net shares: 0 (net value USD: 0.00)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B , ROIC , revenue growth 1y , 6m momentum 58.249772105742935
Sector percentiles: P/E , 6m momentum 50.18106570098293
Industry median P/E: 7.917582417582417; industry median ROIC: 1.6915626385800535
Sector median P/E: 9.286368843069873; sector median ROIC: 1.3915857507207385
WACC: 0.11235
Base cash flow: 0
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for QTRX (Healthcare — Medical Devices, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 3.67
Market cap: 172878944 (USD: 172878944)
P/B ratio: 0.5876998682209833
Debt to equity: 0.1252
Current ratio: 3.72
Return on net tangible assets (%): -8.221210380944568
Buffett classification: The Gruesome
Analyst consensus upside (%): 23.011363636363637
Rule of 40 score: -79.21441377285277
Altman Z-score: -0.6937836528544651 (Distress Zone)
Piotroski F-score: 3 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 1.1007702592167614
Total shareholder yield (%): 1.1007702592167614 (Low Return)
Momentum (%): 1m -2.9100529100529067, 3m 11.89024390243903, 6m -43.3641975308642, 12m -33.39382940108892, composite -20.957137597859813 (Strong Downtrend)
Lynch category: Turnaround (confidence: High)
Screener: long score 2, short score 11, recommendation: Strong Short (Melting Ice Cube)
Revenue growth 1y (%): 20.05076978867899
Revenue deceleration: no
Accrual ratio: 0.0016627665073500391
FCF conversion rate: 1.0372270680120859
Beneish M-score: -2.4584504968746965 (Likely Safe)
ROE (%): -6.07092610955078
Net margin (%): -48.169710284223534
Asset turnover: 0.0927253328715952
Equity multiplier (leverage): 1.3591973267297606
ROE archetype: Low Return
Treasury beta 1y: 0.01679411635984123 (R-squared: 0.008478895210195299)
Insider 90-day net shares: 3500 (net value USD: 9695.00)
ROIC (%): -40.400047499965076 (pretax: -51.139300632867176)
Incremental ROIC 3y (%): -18.313752550498215 (pretax: -23.18196525379521)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B 8.30860534124629, ROIC 47.18100890207715, revenue growth 1y 20.77151335311573, 6m momentum 63.20474777448071
Sector percentiles: P/E , 6m momentum 67.12034383954155
Industry median P/E: 21.626420273203117; industry median ROIC: -5.9391058628332924
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.09843410239162004
Base cash flow: -90837000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for QTS.DE (Healthcare — Diagnostics & Research, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 208.86363636363637
Market cap: 30676219904 (USD: 30676219904)
P/E ratio: 23.808364179492173
P/B ratio: 4.43112319253824
Debt to equity: 2.5354
Current ratio: 0.75
Interest coverage ratio: 2.9427083333333335
Return on net tangible assets (%): -2.88245405262462
Buffett classification: The Great
Rule of 40 score: 5.381744065293203
Altman Z-score: 1.2697154542334608 (Distress Zone)
Piotroski F-score: 4 (Weak)
Dividend yield (%): 0
Buyback yield (%): 1.7994394411288674
Debt paydown yield (%): -0.37814307096186345
Total shareholder yield (%): 1.421296370167004 (Low Return)
Momentum (%): 1m , 3m 19.152721242273493, 6m -11.498459167950688, 12m -23.294840825625013, composite 3.8271310371614025 (Moderate Downtrend)
Lynch category: Stalwart (confidence: Medium)
Screener: long score 2, short score 7, recommendation: Neutral
Revenue growth 1y (%): 8.40950639853748
Net income growth 1y (%): 10.441767068273089
Revenue deceleration: no
Accrual ratio: -0.007246012177326021
FCF conversion rate: 1.7854545454545454
Beneish M-score: -2.5137676996147333 (Likely Safe)
ROE (%): 4.237614608213268
Net margin (%): 6.624909660322814
Asset turnover: 0.13925090994481626
Equity multiplier (leverage): 4.593497187764851
ROE archetype: Low Return
P/E z-score: 6.522379179810044
FCF z-score: 6.522379179810047
Treasury beta 1y: 0.04400973642677471 (R-squared: 0.0008979472067699307)
Insider 90-day net shares: 0 (net value USD: 0.00)
ROIC (%): 9.41755504175711 (pretax: 11.189940307270769)
Incremental ROIC 3y (%): 15.020886493846866 (pretax: 15.483002356109054)
Capital allocation category: Turnaround Compounder
Industry percentiles: P/E 27.941176470588236, P/B 52.20588235294118, ROIC 22.058823529411764, revenue growth 1y 32.35294117647059, 6m momentum 48.529411764705884
Sector percentiles: P/E 26.002865329512893, 6m momentum 41.58309455587392
Industry median P/E: 21.640734060420083; industry median ROIC: 2.9089897435686405
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.09087334458407315
Base cash flow: 1977000000
DCF price per share: base 126.9079828360747, conservative 89.10364487069337, aggressive 175.45103275585757